Skip to main content

Barriers

Even if you have the information, you are a nurse and you want to advocate for better assessment and or screening, you can't get it done. The knowledge might be there but not the values to improve the health care. Even when one is in a position to have some influence.

First of all - congrads on the article!

I'm not sure exactly where you should start. Were you interested in initially working with a subset of women (e.g. maternity)? If that were the case I'd start perhaps with blank and blank (or whoever is OB chief). If you were thinking of a broader population, perhaps blank would be a good place to start.

Just to muddy the waters a little - I totally understand what your mission is and it sounds like a great way of potentially saving lives. On the other hand, keep in mind that everyone is supersensitive to the amount of documentation nsg is required to do and the amount of data collection/assessments that continues to fall on the staff nurse. (I just had this conversation regarding VTE prophylaxis and I suspect more will be coming with the new code status order sheets). I could be wrong, but I suspect you may get resistance is from the managers who may not want their nurses having to answer one more question (and then "do" something depending on the answer). With that being said - maybe you could share your work with Mgmnt Council and feel them out about possible pursuing this as a quality initiative.

Please understand - I am not trying to be a downer. I just have concerns that the acute care nurse on the general med/surg (or critical care) unit can handle be asked to do much more than they are already done.

Again - congrads on the article.

Comments

Popular posts from this blog

Get the Facts About Genetic Colon Cancer

Get the Facts: http://genefacts.org Lynch syndrome is a cancer predisposition syndrome caused by inherited mutations in genes responsible for correcting DNA replication errors. Individuals with Lynch syndrome have a greatly increased risk for colorectal, endometrial, and stomach cancers, and a moderately increased risk for other cancers. Key Points 1-3% of colon cancers attributable to Lynch syndrome Dominant inheritance with reduced penetrance (not all patients with mutations will manifest disease) Diagnosis based on clinical and family history, tumor pathology and/or genetic testing Screening and prophylactic surgeries effective in reducing some, but not all cancer risks Mutations in any of several genes can cause the syndrome

Cancer Survivors

Just read a story about one woman's cancer experience. I bet everyone has a story about what goes through your mind when you are told you have cancer. Her thought were about her stunned family members, one crying and the other in shock. I bet there are quite a few stories that could be qualitatively studied. Those experiences could help nurses better help patients during this time.

My Publication, "Hereditary non-polyposis colon cancer: change the name to protect the innocent." Cited in World Journal of Gastroenterology

Estradiol agonists inhibit human LoVo colorectal-cancer cell proliferation and migration t... Hsi-Hsien Hsu, Wei-Wen Kuo, Da-Tong Ju... World journal of gastroenterology : WJG 11/2014 20(44):16665-73. World Journal of Gastroenterology : WJG 11/2014; 20(44):16665-73. DOI: 10.3748/wjg.v20.i44.16665 Source: PubMed ABSTRACT To investigate the effects of 17β-estradiol via estrogen receptors (ER) or direct administration of ER agonists on human colorectal cancer. LoVo cells were established from the Bioresource Collection and Research Center and cultured in phenol red-free DMEM (Sigma, United States). To investigate the effects of E2 and/or ER selective agonists on cellular proliferation, LoVo colorectal cells were treated with E2 or ER-selective agonists for 24 h and 48 h and subjected to the MTT (Sigma) assay to find the concentration. And investigate the effects of E2 and/or ER selective agonists on cell used western immunoblotting to find out the diver...